行情

OMER

OMER

奥麦罗制药
NASDAQ

实时行情|Nasdaq Last Sale

13.34
-0.70
-4.99%
交易中 12:46 11/14 EST
开盘
13.89
昨收
14.04
最高
13.95
最低
13.31
成交量
23.05万
成交额
--
52周最高
20.92
52周最低
10.30
市值
6.57亿
市盈率(TTM)
-6.4051
分时
5日
1月
3月
1年
5年

分析师评级

6位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

OMER 新闻

  • SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Omeros Corporation - OMER
  • ACCESSWIRE.22小时前
  • Edited Transcript of OMER earnings conference call or presentation 12-Nov-19 9:30pm GMT
  • Thomson Reuters StreetEvents.1天前
  • What Kind Of Shareholder Appears On The Omeros Corporation's (NASDAQ:OMER) Shareholder Register?
  • Simply Wall St..1天前
  • Omeros Corporation (OMER) CEO Greg Demopulos on Q3 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript.1天前

更多

所属板块

生物技术和医学研究
-0.20%
制药与医学研究
-0.56%

热门股票

名称
价格
涨跌幅

OMER 简况

Omeros Corporation is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases and disorders of the central nervous system. The Company’s drug product OMIDRIA (phenylephrine and ketorolac intraocular solution) is used during cataract surgery or intraocular lens (IOL) replacement. The Company’s clinical-stage development programs are focused on complement-associated thrombotic microangiopathies, complement-mediated glomerulonephropathies, Huntington’s disease and cognitive impairment, and addictive and compulsive disorders. It also offers a diverse group of preclinical programs and platforms that are used to unlock new G protein-coupled receptor (GPCR) drug targets and to generate antibodies.
展开

Webull提供Omeros Corporation的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。